FairoozKabbinavarMD

Genitourinary Oncology, Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

Medical Director of the UCLA Kidney Cancer Program, Associate Professor of Medicine in the Division of Hematology and Oncology in The David Geffen School of Medicine at UCLA, Director of the Hematology/Oncology Fellowship Program in the Division of Hemato

Join to view full profile

Dr. Kabbinavar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kabbinavar's full profile

Already have an account?

Office
11055 Flintkote Ave
San Diego, CA 92121
Phone+1 310-746-6500

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1986 - 1989
Indira Gandhi Medical CollegeClass of 1979

Certifications & Licensure

MA State Medical License 1989 - 2026
CA State Medical License 1989 - 2025
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy Start of enrollment: 1999 Nov 01
Completed
Phase 2
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms Start of enrollment: 1999 Sep 01
Terminated
Phase 3
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 2002 Oct 01
Completed
Phase 2
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF) Start of enrollment: 2003 Jun 01
Completed
Phase 1, Phase 2
Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2004 Oct 01
Withdrawn
Phase 1, Phase 2
Cetuximab in Treating Patients With Recurrent or Progressive Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2005 Mar 01
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299) Start of enrollment: 2005 May 01
Completed
Phase 2
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2005 Sep 01
Unknown status
Phase 2
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Start of enrollment: 2007 Dec 01
Completed
Phase 2
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma Start of enrollment: 2010 Oct 01
Withdrawn
Phase 2
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy Start of enrollment: 2013 Oct 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

135 citations
ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With B...
Bruce E. Johnson, Fairooz F. Kabbinavar, Louis Fehrenbacher, John D. Hainsworth, Saifuddin M. Kasubhai
Journal of Clinical Oncology. 2013-11-01
1913 citations
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn, Aaron S. Mansfield, Aleksandra Szczesna, Libor Havel, Maciej Krzakowski
The New England Journal of Medicine. 2018-09-25
8233 citations
BEVACIZUMAB PLUS IRINOTECAN, FLUOROURACIL, AND LEUCOVORIN FOR METASTATIC COLORECTAL CANCER
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John D. Hainsworth
The New England Journal of Medicine. 2004-06-03

Journal Articles

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
David S Shames, Leora Horn, Fairooz Kabbinavar, The New England Journal of Medicine

Press Mentions

Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateMarch 2nd, 2023
UCLA, VA Team up to Improve Cancer Care for VeteransSeptember 30th, 2015